Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC for dry eye syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Apr 2025: Trial registered, NCT06905834

The trials

NCT06905834: Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments

State
Not started
Phase
Phase 2
People
30 planned
Started
Dec 2026
Primary completion
Jan 2029
Arms
6.25 million ASCs / 2,5ml of Ringer Lactato + 1% of HSA., 12.5 million ASCs / 2,5 ml of Ringer Lactato + 1% of HSA.
Results
None posted
  1. 1 Apr 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.